[{"data":1,"prerenderedAt":201},["ShallowReactive",2],{"drug-abatacept":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":45,"contraindications":103,"warnings":104,"renal":112,"monitoring":113,"interactions":114,"review":115,"examples":117,"atc":135,"iran":137,"links":144,"populations":162,"usApproval":196},"abatacept",1,{"fa":7,"en":8},"آباتاسپت","Abatacept","antineoplastic-immunomodulating",{"fa":11,"en":12},"تعدیل‌کننده هم‌تحریکی سلول T","T-cell co-stimulation modulator",[14],{"name":15,"market":16},"Orencia","US",[18,19,7],"orencia","اورنسیا",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"vial-250","powder-for-injection","iv","250 mg vial",{"amount":27,"unit":28,"perUnit":29},250,"mg","vial",[16],[32],{"source":33,"section":34},"fda-orencia","3",{"id":36,"form":37,"route":38,"label":39,"concentration":40,"markets":42,"refs":43},"pfs-125","injection","sc","125 mg\u002FmL prefilled syringe or ClickJect",{"amount":41,"unit":28,"perVolumeMl":5},125,[16],[44],{"source":33,"section":34},[46,83],{"id":47,"disease":48,"label":49,"population":52,"type":56,"unit":28,"dose":57,"refs":69,"durationDays":72,"allowedFormulations":73,"notes":74},"ra-iv","rheumatoid-arthritis",{"fa":50,"en":51},"آرتریت روماتوئید یا پسوریاتیک بزرگسال (وریدی) — هفته ۰، ۲، ۴ و سپس هر ۴ هفته؛ زیر ۶۰ kg: ۵۰۰، ۶۰ تا ۱۰۰: ۷۵۰، بالای ۱۰۰: ۱۰۰۰ mg","RA or PsA, adults (IV) — weeks 0, 2, 4 then every 4 weeks; \u003C60 kg: 500, 60–100: 750, >100: 1000 mg",{"minAge":53},{"value":54,"unit":55},18,"year","weightBand",{"weightBands":58},[59,63,66],{"minWeightKg":60,"maxWeightKg":61,"perDose":62,"dosesPerDay":5},0,59.99,500,{"minWeightKg":61,"maxWeightKg":64,"perDose":65,"dosesPerDay":5},100,750,{"minWeightKg":64,"maxWeightKg":67,"perDose":68,"dosesPerDay":5},null,1000,[70],{"source":33,"section":71},"2",{"min":5,"max":5},[22],[75],{"text":76,"refs":79},{"fa":77,"en":78},"انفوزیون ۳۰ دقیقه. همراه مهارکننده JAK یا داروی بیولوژیک (مثل ضد TNF) نه.","30-minute infusion. Not with JAK inhibitors or biologic DMARDs (e.g. TNF antagonists).",[80,81],{"source":33,"section":71},{"source":33,"section":82},"2.1",{"id":84,"disease":48,"label":85,"population":88,"type":90,"unit":28,"dose":91,"refs":92,"durationDays":94,"allowedFormulations":95,"notes":96},"ra-sc",{"fa":86,"en":87},"آرتریت روماتوئید یا پسوریاتیک بزرگسال (زیرجلدی) — ۱۲۵ mg هفتگی","RA or PsA, adults (SC) — 125 mg once weekly",{"minAge":89},{"value":54,"unit":55},"fixed",{"perDose":41,"dosesPerDay":5},[93],{"source":33,"section":71},{"min":5,"max":5},[36],[97],{"text":98,"refs":101},{"fa":99,"en":100},"بارگذاری وریدی اختیاری بر اساس وزن پیش از اولین دوز زیرجلدی.","Optional weight-based IV loading dose before the first SC dose.",[102],{"source":33,"section":71},[],[105],{"text":106,"refs":109},{"fa":107,"en":108},"عفونت (بیشتر با ضد TNF همزمان)؛ حساسیت؛ واکسن زنده نه؛ عوارض بیشتر در COPD؛ فعال شدن CMV و EBV در پیوند.","Infections (more with concurrent TNF antagonists); hypersensitivity; no live vaccines; more adverse effects in COPD; CMV\u002FEBV reactivation in transplant.",[110],{"source":33,"section":111},"5",[],[],[],{"status":116,"reviewer":67,"date":67},"unverified",[118,123,127,131],{"regimen":47,"formulation":22,"input":119,"expect":122},{"ageYears":120,"weightKg":121},50,55,{"perDose":62},{"regimen":47,"formulation":22,"input":124,"expect":126},{"ageYears":120,"weightKg":125},80,{"perDose":65},{"regimen":47,"formulation":22,"input":128,"expect":130},{"ageYears":120,"weightKg":129},110,{"perDose":68},{"regimen":84,"formulation":36,"input":132,"expect":134},{"ageYears":120,"weightKg":133},70,{"perDose":41,"mlPerDose":5},[136],"L04AA24",{"status":138,"refs":139},"not-found",[140],{"source":141,"section":142,"url":143},"darooyab-generic","G-4167\u002FAbatacept","https:\u002F\u002Fwww.darooyab.ir\u002FG-4167\u002FAbatacept",[145,149,153,157,160],{"kind":146,"url":147,"label":148},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125118","BLA125118",{"kind":150,"url":151,"label":152},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb","FDA Orencia",{"kind":154,"url":155,"label":156},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa606016.html","Abatacept Injection",{"kind":158,"url":159,"label":136},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L04AA24",{"kind":161,"url":143,"label":8},"darooyab",{"pregnancy":163,"lactation":172,"pediatric":180,"geriatric":188},{"level":164,"text":165,"quote":168,"refs":169},"caution",{"fa":166,"en":167},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The data with ORENCIA use in pregnant women are insufficient to inform on drug-associated risk.",[170],{"source":33,"section":171},"8.1",{"level":164,"text":173,"quote":176,"refs":177},{"fa":174,"en":175},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of abatacept in human milk, the effects on the breastfed infant, or the effects on milk production.",[178],{"source":33,"section":179},"8.2",{"level":164,"text":181,"quote":184,"refs":185},{"fa":182,"en":183},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Polyarticular Juvenile Idiopathic Arthritis The safety and effectiveness of ORENCIA for reducing signs and symptoms in patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) have been established (ORENCIA may be used as monotherapy or concomitantly with …",[186],{"source":33,"section":187},"8.4",{"level":164,"text":189,"quote":192,"refs":193},{"fa":190,"en":191},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because there is a higher incidence of infections and malignancies in the geriatric population in general, caution should be used when treating geriatric patients.",[194],{"source":33,"section":195},"8.5",{"kind":197,"refs":198,"id":148},"BLA",[199],{"source":33,"section":200},"SPL approval \u002F marketing category",1792191523086]